KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Assets: 2018-2025

Historic Non-Current Assets for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $205.2 million.

  • Castle Biosciences' Non-Current Assets rose 20.86% to $205.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $205.2 million, marking a year-over-year increase of 20.86%. This contributed to the annual value of $171.1 million for FY2024, which is 8.48% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Non-Current Assets is $205.2 million, which was up 4.67% from $196.1 million recorded in Q2 2025.
  • Castle Biosciences' 5-year Non-Current Assets high stood at $205.2 million for Q3 2025, and its period low was $10.7 million during Q1 2021.
  • Over the past 3 years, Castle Biosciences' median Non-Current Assets value was $162.7 million (recorded in 2024), while the average stood at $168.2 million.
  • Per our database at Business Quant, Castle Biosciences' Non-Current Assets surged by 1,018.03% in 2021 and then fell by 6.39% in 2025.
  • Castle Biosciences' Non-Current Assets (Quarterly) stood at $108.8 million in 2021, then surged by 42.46% to $155.0 million in 2022, then climbed by 1.72% to $157.7 million in 2023, then increased by 8.48% to $171.1 million in 2024, then climbed by 20.86% to $205.2 million in 2025.
  • Its last three reported values are $205.2 million in Q3 2025, $196.1 million for Q2 2025, and $152.3 million during Q1 2025.